IRIS
MINOTTI, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 9.434
NA - Nord America 5.494
EU - Europa 2.082
SA - Sud America 609
Continente sconosciuto - Info sul continente non disponibili 183
AF - Africa 118
OC - Oceania 34
Totale 17.954
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 6.306
US - Stati Uniti d'America 5.179
CN - Cina 1.299
HK - Hong Kong 1.001
IT - Italia 843
BR - Brasile 402
GB - Regno Unito 292
FR - Francia 235
VN - Vietnam 218
DE - Germania 169
RU - Federazione Russa 147
BD - Bangladesh 140
CA - Canada 122
IN - India 94
IL - Israele 80
NL - Olanda 80
CZ - Repubblica Ceca 72
MX - Messico 69
AR - Argentina 65
SC - Seychelles 48
ID - Indonesia 43
CO - Colombia 39
EC - Ecuador 34
ES - Italia 34
FI - Finlandia 34
TR - Turchia 34
AU - Australia 32
UA - Ucraina 32
JP - Giappone 28
IQ - Iraq 27
CR - Costa Rica 26
BE - Belgio 23
MY - Malesia 22
PH - Filippine 22
VE - Venezuela 21
PL - Polonia 20
ZA - Sudafrica 19
PY - Paraguay 18
SA - Arabia Saudita 16
CL - Cile 15
JM - Giamaica 14
MD - Moldavia 14
NI - Nicaragua 14
PK - Pakistan 14
SV - El Salvador 14
EE - Estonia 13
HN - Honduras 11
SE - Svezia 11
AE - Emirati Arabi Uniti 10
JO - Giordania 10
PE - Perù 10
TT - Trinidad e Tobago 10
GP - Guadalupe 9
GT - Guatemala 9
TN - Tunisia 9
UZ - Uzbekistan 9
AL - Albania 8
MA - Marocco 8
NP - Nepal 8
TW - Taiwan 8
PT - Portogallo 7
EG - Egitto 6
LT - Lituania 6
TH - Thailandia 6
AT - Austria 5
HU - Ungheria 5
IE - Irlanda 5
RO - Romania 5
DO - Repubblica Dominicana 4
AM - Armenia 3
AO - Angola 3
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
BY - Bielorussia 3
GE - Georgia 3
HR - Croazia 3
IR - Iran 3
KR - Corea 3
KW - Kuwait 3
NA - Namibia 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
BF - Burkina Faso 2
BO - Bolivia 2
CI - Costa d'Avorio 2
CW - ???statistics.table.value.countryCode.CW??? 2
DK - Danimarca 2
DM - Dominica 2
DZ - Algeria 2
ET - Etiopia 2
GA - Gabon 2
KG - Kirghizistan 2
KN - Saint Kitts e Nevis 2
KZ - Kazakistan 2
LB - Libano 2
LV - Lettonia 2
LY - Libia 2
MM - Myanmar 2
NG - Nigeria 2
Totale 17.738
Salva come PNG Salva come JPEG
Città #
San Jose 1.263
Ashburn 1.125
Hong Kong 992
Singapore 815
Rome 564
Hefei 455
Beijing 315
Council Bluffs 311
Boardman 270
Columbus 234
London 206
Lauterbourg 199
Shanghai 149
Dallas 122
Santa Clara 113
Los Angeles 85
Ho Chi Minh City 74
Munich 71
New York 62
San Francisco 61
Redmond 57
Brno 54
Phoenix 49
Amsterdam 48
Hanoi 45
São Paulo 38
Pune 37
Mexico City 33
Toronto 33
Brooklyn 29
Chicago 25
Washington 24
San José 21
Buffalo 20
Seattle 20
Brasília 19
Turku 19
Haiphong 18
Atlanta 17
Bogotá 17
Melbourne 17
Olomouc 17
Hasselt 16
Milan 16
Tokyo 16
West Jordan 16
Naples 15
The Dalles 15
Helsinki 14
Managua 14
Quito 14
Rio de Janeiro 14
Warsaw 14
Boston 12
Frankfurt am Main 12
Guangzhou 12
Las Vegas 12
Manchester 12
San Salvador 12
Chennai 11
Canberra 10
Charlotte 10
Kuala Lumpur 10
Montreal 10
Orem 10
Palermo 10
Amman 9
Caracas 9
Catania 9
Johannesburg 9
New Delhi 9
North Bergen 9
Nuremberg 9
Philadelphia 9
Riyadh 9
Asunción 8
Biên Hòa 8
Buenos Aires 8
Fortaleza 8
Guayaquil 8
Hangzhou 8
Miami 8
Tashkent 8
Bengaluru 7
Da Nang 7
Dhaka 7
Lima 7
Oklahoma City 7
Paris 7
Queens 7
Ankara 6
Baghdad 6
Belo Horizonte 6
Campinas 6
Chaguanas 6
Curitiba 6
Florence 6
Guatemala City 6
Haikou 6
Petaling Jaya 6
Totale 8.704
Salva come PNG Salva come JPEG
Nome #
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 247
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 246
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 228
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 224
Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study. 218
Proceedings of an International Workshop on Anthracycline Cardiotoxicity 217
Cancer drugs and QT prolongation: weighing risk against benefit 215
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 215
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 214
An investigation into thee mechanism of citrateFE2+-dependent lipid peroxidation 214
A supposed role for superoxide dismutase in the control of tumor growth 213
Cell Biology and Toxicology: Special Issue on Cardiovascular Liability of Drugs 213
Minimal sampling colistin pharmacokinetics in critically ill patients 213
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 211
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 211
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 210
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines 208
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 204
Acute Heart Failure 29 Years After Treatment for Childhood Cancer 201
A Special Section on Clinical Pharmacology-Editorial 200
Adriamycin dependent release of iron from human lung tumor microsomes : Biochemical mechanisms and clinical implications 199
Cardio-oncology in clinical studies and real life 197
Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes 189
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 187
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 172
Anthracycline Cardiotoxicity 162
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). 156
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 152
Anthracycline metabolism and toxicity in human myocardium : Comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with reduced formation and [4Fe-4S]-reactivity of its secondary alcohol metabolite 144
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 143
Anthracyclines 142
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 138
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 131
Anthracycline Cardiotoxicity 123
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 119
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 119
An Invitation from the Editors of Cardio-Oncology 118
Adriamycin dependent release of iron from microsomal membranes 117
Activation of heme oxygenase and consequent carbon monoxide formation inhibits the release of arginine vasopressin from rat hypothalamic explants. Molecular linkage between heme catabolism and neuroendocrine function. Mol Brain Res. 116
Anthracycline cardiotoxicity 115
Adriamycin alcohol dependent iron mobilization : A novel mechanism of adriamycin cardiotoxicity? 114
All Eyes on Me, Please: Ocular Palonosetron for the Cancer Patient with Nausea and Vomiting 113
Cardiotoxicity of antitumor drugs 113
An introduction to the metabolic determinants of anthracycline cardiotoxicity 112
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 111
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 110
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 110
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 108
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement 101
Isavuconazole: case report and pharmacokinetic considerations 95
The interaction of short chain coenzyme Q analogs with different redox states of myoglobin 90
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 88
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 86
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 84
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma 84
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 82
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 82
Drug-induced hepatotoxicity in cancer patients - implication for treatment 82
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 82
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 81
Early diagnosis of acute coronary syndrome. 79
Superoxide-dependent lipid peroxidation and vitamin E content of microsomes from hepatomas with different growth rates. 78
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 77
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology. 77
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 76
Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond 75
Pharmacology of Cardio-Oncology 74
Doxorubicin-Dexrazoxane from day 1 for soft-tissue sarcomas: The road to cardioprotection 74
The concomitant management of cancer therapy and cardiac therapy 73
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 73
What is cardiotoxicity? 71
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 71
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 70
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 70
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 70
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 70
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin 70
Doxorubicin toxicity in human heart: role of C-13 metabolite, c-aconitase and iron 69
Novel mechanisms for the inhibition of low density lipoprotein oxidation by ascorbic acid. 69
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 69
Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases 69
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 68
Cardiotoxicity of antitumor drugs 68
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 67
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence 66
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 66
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 66
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. 66
Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study 65
Cancer incidence and mortality in patients diagnosed with heart failure: results from an updated systematic review and meta-analysis 65
Pharmacological Foundation of Cardio-Oncology 65
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 65
Post-transcriptional control of hepatic oxidative stress respone 65
Vitamin E inhibits enhanced F2 isoprostane biosynthesis in type IIA hypercholesterolemia excretion 65
Nitric oxide and peroxynitrite activate the iron regulatory protein-1 of J774A.1 macrophages by direct disassembly of the Fe-S cluster of cytoplasmic aconitase 65
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 63
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology 62
Quantitative evaluation of the activity of the malate-aspartate shuttle in Ehrlich ascites tumor cells. 62
Anthracycline secondary alcohol metabolite formation in human or rabbit heart ; Biochemical aspects and pharmacological implications 62
The [Fe-S] cluster of cytoplasmic aconitase as a novel target of anthracycline cardiotoxicity 62
Totale 11.946
Salva come PNG Salva come JPEG
Categoria #
all - tutte 125.075
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 125.075
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022521 0 0 0 0 0 1 2 214 7 7 7 283
2022/2023108 2 4 5 8 7 5 13 0 2 7 51 4
2023/2024776 22 87 29 55 96 329 9 29 6 24 10 80
2024/20257.426 150 67 268 29 72 168 91 32 690 586 2.541 2.732
2025/20266.565 714 289 311 693 260 348 1.881 527 504 525 267 246
2026/20272.552 135 684 545 830 358 0 0 0 0 0 0 0
Totale 17.954